Sling Therapeutics develops pharmaceutical treatments for thyroid eye disease, a condition that can affect tissues surrounding the eyes.
Sling Therapeutics has raised $123.0M in total funding. The most recent round was Series C. The last funding was announced in September 2026.
Sling Therapeutics's investors include TPG, Forbion Capital Partners, The Rise Fund, Sectoral Asset Management.
Sling Therapeutics is headquartered in Ann Arbor, United States.
Sling Therapeutics develops pharmaceutical treatments for thyroid eye disease, a condition that can affect tissues surrounding the eyes.
Sling Therapeutics is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Sling Therapeutics — Funding & Investors." VCBacked, September 16, 2026, https://www.vcbacked.co/company/sling-therapeutics. Accessed November 15, 2026.
VCBacked. (2026). Sling Therapeutics — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/sling-therapeutics
{{cite web |title=Sling Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/sling-therapeutics |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Sling Therapeutics? Request a listing update